‘Demystify’ Pricing, Say UK Parliamentarians
Executive Summary
UK members of parliament have called on pharmaceutical companies to be more transparent in their pricing process and to improve the way they gather and present data for health technology appraisals. They also say that industry rebates should be ring fenced to fund new medicines.
You may also be interested in...
UK Politicians Want NICE To Use Conditional Reimbursement
A UK parliamentary report has called for the HTA body NICE to consider the use of conditional reimbursement recommendations and more flexible cost-effectiveness thresholds in its ongoing methods review.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.